Roles of Short-Chain Fatty Acids in Kidney Diseases
The human intestinal tract harbors a diverse and complex microbial community, which plays a crucial role in maintaining gut homeostasis and overall host health. Among the metabolites produced by gut microbiota, short-chain fatty acids (SCFAs) have gained significant attention for their potential health benefits. SCFAs are straight-chain saturated fatty acids with fewer than six carbon atoms, including acetate (two carbons), propionate (three carbons), butyrate (four carbons), and valproic acid (five carbons). These SCFAs are primarily produced through the fermentation of dietary fibers by anaerobic bacteria in the distal small intestine and colon. Once produced, SCFAs can be absorbed into the bloodstream, where they exert various physiological effects.
In the context of kidney diseases, SCFAs have been shown to influence multiple aspects of renal physiology, including inflammation, immunity, fibrosis, blood pressure regulation, and energy metabolism. This article provides a comprehensive overview of the roles of SCFAs in kidney diseases, focusing on their mechanisms of action and potential therapeutic implications.
Introduction to SCFAs and Kidney Diseases
Kidney diseases are often associated with uncontrolled blood pressure, chronic inflammation, oxidative stress, imbalanced immune responses, and metabolic dysfunction, all of which contribute to the progressive deterioration of renal function. SCFAs, as metabolites of gut microbiota, have been implicated in modulating these pathological processes. The primary mechanisms through which SCFAs exert their effects include the activation of transmembrane G protein-coupled receptors (GPCRs) such as Gpr41, Gpr43, and olfactory receptor 78 (Olfr78), as well as the inhibition of histone deacetylases (HDACs).
SCFAs have been shown to possess anti-inflammatory, anti-oxidative, anti-diabetic, and anti-cancer properties. However, their roles in the gut-kidney axis and their potential therapeutic effects in kidney diseases are still not fully understood. This article aims to explore the current understanding of SCFAs in kidney diseases, focusing on their effects on inflammation, immunity, fibrosis, blood pressure, and metabolism.
Effects of SCFAs on Inflammation in Kidney Diseases
Inflammation is a key driver of both acute kidney injury (AKI) and chronic kidney disease (CKD). SCFAs have been shown to modulate inflammation in both intestinal and extra-intestinal environments, exerting protective effects in various inflammatory conditions, including inflammatory bowel disease and allergic airway disease. In the context of kidney diseases, SCFAs have been shown to improve renal dysfunction in both AKI and CKD through their anti-inflammatory properties.
In animal models of AKI, including contrast-induced and ischemia/reperfusion-induced kidney injury, the administration of SCFAs significantly improved acute renal dysfunction. The key mechanism underlying this protective effect is the reduction of inflammatory cytokines and chemokines, both locally and systemically, through the inhibition of the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling pathway. Acetate, in particular, has been shown to inhibit HDAC activity in T cells, thereby influencing Toll-like receptor 4 (TLR4)-induced NADPH oxidase 2 (NOX2)/reactive oxygen species (ROS) signaling and exerting anti-inflammatory effects.
In CKD, dietary interventions that increase the production of SCFAs, such as the supplementation of dietary fiber or xylooligosaccharide (XOS), have been shown to improve intestinal epithelial tight junctions and reduce inflammation. These effects are positively correlated with improvements in clinical manifestations of CKD in both animal models and patients with end-stage renal disease (ESRD). For example, propionic acid supplementation in hemodialysis patients has been shown to reduce pro-inflammatory parameters, including C-reactive protein, interleukin (IL)-2, IL-17, IL-6, and interferon-gamma, while increasing the anti-inflammatory cytokine IL-10. These changes are associated with a reduction in ferritin levels and an increase in hemoglobin, which may further contribute to improved survival outcomes.
However, the effects of SCFAs on inflammation are not universally beneficial. In some cases, SCFAs have been shown to exacerbate inflammation. For example, treatment with valproic acid failed to block the accumulation of monocytes, macrophages, and neutrophils in angiotensin II (Ang II)-treated rats. Additionally, chronic administration of high doses of SCFAs in mice has been shown to induce the generation of Th1 and Th17 cells in the ureteropelvic junction and proximal ureter, leading to kidney inflammation and hydronephrosis. These findings suggest that the effects of SCFAs on inflammation are complex and may depend on the specific type of SCFA, the dose, and the context in which they are administered.
Effects of SCFAs on Immunity in Kidney Diseases
SCFAs play a significant role in modulating both innate and adaptive immunity. In the context of kidney diseases, SCFAs have been shown to influence immune cell production, differentiation, and function, thereby affecting the host’s immune response to injury and infection.
One of the key mechanisms through which SCFAs modulate immunity is by inducing the production of regulatory T cells (Tregs). SCFAs, particularly butyrate, have been shown to promote Treg differentiation through the inhibition of HDAC activity and the modulation of cellular bioenergetic metabolism. Additionally, SCFAs can indirectly influence T-cell differentiation by exerting broadly immunosuppressive or tolerogenic effects on antigen-presenting cells.
In CKD, the production of SCFAs has been shown to enhance intestinal innate immunity by increasing the expression of defensin alpha 5 (Defa5), a microbicidal peptide involved in host defense against pathogenic bacteria. Dietary interventions that increase SCFA production, such as XOS supplementation, have been shown to inhibit Defa5 expression, thereby promoting a more favorable gut microbiota profile and enhancing the host’s resistance to infection.
However, the effects of SCFAs on immunity are not always protective. In some cases, SCFAs can lead to immune-mediated damage if not properly regulated. For example, the activation of SCFA receptors in immune and epithelial cells can lead to the production of pro-inflammatory cytokines and chemokines, exacerbating inflammation and tissue damage. These findings highlight the need for further research to better understand the complex roles of SCFAs in immune regulation and their potential therapeutic implications in kidney diseases.
Effects of SCFAs on Fibrosis in Kidney Diseases
Renal fibrosis is a common pathological feature of CKD and is characterized by the excessive deposition of extracellular matrix components, leading to the progressive loss of renal function. SCFAs have been shown to exert anti-fibrotic effects in various animal models of kidney disease, primarily through their ability to modulate immune-inflammatory processes and inhibit key signaling pathways involved in fibrosis.
In animal models of CKD, the administration of acetate or butyrate has been shown to attenuate glomerular and tubulointerstitial fibrosis, as well as collagen deposition. These effects are mediated, in part, by the inhibition of transforming growth factor-beta 1 (TGF-β1) signaling, a key pathway involved in the pathogenesis of renal fibrosis. Additionally, SCFAs have been shown to inhibit histone deacetylase activity, thereby reducing the phosphorylation of extracellular signal-regulated kinase (ERK) and blocking the proliferation of pericytes, which contribute to fibrosis.
Dietary interventions that increase SCFA production, such as XOS supplementation, have also been shown to reduce fibrosis in adenine-induced kidney damage. These effects are associated with a decrease in M2 macrophages, which play a key role in the development of renal fibrosis.
However, the effects of SCFAs on fibrosis are not universally beneficial. In some cases, SCFAs have been shown to promote fibrosis. For example, in porcine kidney fibroblasts, the administration of sodium butyrate has been shown to increase the expression of Wilms tumor 1 (WT1), a transcription factor involved in cell proliferation and development, which may contribute to fibrosis. These findings suggest that the effects of SCFAs on fibrosis are complex and may depend on the specific type of SCFA, the dose, and the context in which they are administered.
Effects of SCFAs on Blood Pressure in Kidney Diseases
Hypertension is a common complication of CKD and a major risk factor for the progression of kidney disease. SCFAs have been shown to play a role in blood pressure regulation, primarily through their interaction with GPCRs expressed in the kidney and vasculature.
In hemodialysis patients, the supplementation of sodium propionate has been shown to reduce systolic blood pressure by 10%, although diastolic blood pressure remains unchanged. The effects of SCFAs on blood pressure are mediated, in part, by their interaction with olfactory receptor 78 (Olfr78), which is expressed on the afferent arteriole of the kidney and plays a role in renin secretion and vasoconstriction. Additionally, SCFAs can interact with Gpr41, a GPCR expressed in the renal vasculature, which has been shown to have hypotensive effects.
However, the effects of SCFAs on blood pressure are complex and may depend on the specific type of SCFA and the context in which they are administered. For example, the administration of propionate to Gpr41-deficient mice has been shown to induce blood pressure elevation, suggesting that Gpr41 is needed to counterbalance the pressor response to SCFAs. Additionally, the regulation of SCFA receptors in the kidney may be influenced by microRNAs (miRNAs), which are altered in hypertensive kidney disease.
Effects of SCFAs on Metabolism in Kidney Diseases
Metabolic dysfunction is a common feature of CKD and is associated with insulin resistance, impaired glucose metabolism, and increased cardiovascular risk. SCFAs have been shown to play a role in the regulation of metabolism, including body weight control, insulin sensitivity, glucose homeostasis, and cholesterol synthesis.
In hemodialysis patients, the supplementation of propionic acid has been shown to improve glucose homeostasis, as evidenced by a decline in fasting insulin levels and an improvement in the homeostasis model assessment (HOMA) index. These effects are associated with a reduction in oxidative stress and inflammation, which may contribute to improved metabolic outcomes.
However, the effects of SCFAs on metabolism in kidney diseases are not fully understood, and further research is needed to explore their potential therapeutic implications.
Conclusion
The roles of SCFAs in kidney diseases are complex and multifaceted, with potential therapeutic implications in inflammation, immunity, fibrosis, blood pressure regulation, and metabolism. While growing evidence suggests that SCFAs exert protective effects in various animal models of kidney disease, their roles in human kidney diseases are still not fully understood. Further research, including clinical trials and animal experiments, is needed to better understand the mechanisms underlying the effects of SCFAs in kidney diseases and to explore their potential as therapeutic agents.
doi.org/10.1097/CM9.0000000000000228
Was this helpful?
0 / 0